Are nonlethal targets useful for developing novel antimicrobials?

Future Microbiology

Volumn 6, Issue 6, 2011, Pages 605-607

  Martínez, José L ^a   Rojo, Fernando ^a   Vila, Jordi ^b  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antivirulence antibiotics; inhibitor of antibiotic resistance; MDR; multidrug resistance; quorum sensing; type three secretion

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CLAVULANIC ACID;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICROBIAL VIABILITY; VIRULENCE;

EID: 79959778616     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.47     Document Type: Review

References (18)

1. Lange RP, Locher HH, Wyss PC, Then RL: The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des. 13(30), 3140-3154 (2007 (Pubitemid 350130963)
2. Reading C, Cole M: Clavulanic acid: a β-lactamase-inhibiting β-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother. 11(5), 852-857 (1977 (Pubitemid 8119260)
3. Martinez JL, Cercenado E, Rodriguez- Creixems M, Vincente-Perez MF, Delgado- Iribarren A, Baquero F: Resistance to β-lactam/clavulanate. Lancet 2(8573), 1473 (1987
4. Martinez JL, Vicente MF, Delgado-Iribarren A, Perez-Diaz JC, Baquero F: Small plasmids are involved in amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob. Agents Chemother. 33(4), 595 (1989 (Pubitemid 19094303)
5. Drawz SM, Bonomo RA: Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23(1), 160-201 (2010
6. Ball P: Conclusions: the future of antimicrobial therapy - Augmentin and beyond. Int. J. Antimicrob. Agents 30(Suppl. 2), S139-S141 (2007
7. Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP: 4,7-dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived β-lactamase inhibitor with class A, C, and D activity. Bioorg. Med. Chem. Lett. 20(8), 2622-2624 (2010
8. Kiener PA, Waley SG: Reversible inhibitors of penicillinases. Biochem. J. 169(1), 197-204 (1978 (Pubitemid 8270577)
9. Vila J, Martinez JL: Clinical impact of the over-expression of efflux pump in nonfermentative gram-negative bacilli, development of efflux pump inhibitors. Curr. Drug Targets 9(9), 797-807 (2008
10. Lomovskaya O, Warren MS, Lee A et al.: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45(1), 105-116 (2001 (Pubitemid 32039101)
11. Rasko DA, Sperandio V: Anti-virulence strategies to combat bacteria-mediated disease. Nat. Rev. 9(2), 117-128 (2010
12. Hu Y, Xie GH, Chen QX, Fang XM: Small molecules in treatment of sepsis. Curr. Drug Targets 12(2), 256-262 (2011
13. Rasko DA, Moreira CG, Li de R et al.: Targeting QseC signaling and virulence for antibiotic development. Science 321(5892), 1078-1080 (2008
14. Fajardo A, Martinez-Martin N, Mercadillo M et al.: The neglected intrinsic resistome of bacterial pathogens. PLoS One 3(2), e1619 (2008
15. Tamae C, Liu A, Kim K et al.: Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J. Bacteriol. 190(17), 5981-5988 (2008
16. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL: Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to β-lactam antibiotics. Antimicrob. Agents Chemother. 54(10), 4159-4167 (2010
17. Linares JF, Moreno R, Fajardo A et al.: The global regulator Crc modulates metabolism, susceptibility to antibiotics and virulence in Pseudomonas aeruginosa. Environ. Microbiol. 12, 3196-3212 (2010
18. Martinez JL, Fajardo A, Garmendia L et al.: A global view of antibiotic resistance. FEMS Microbiol. Rev. 33(1), 44-65 (2009